A randomized double‐blinded placebo‐controlled study to evaluate an effective ciclosporin dose for the treatment of feline hypersensitivity dermatitis

Abstract

Results suggest that 7.0 mg/kg ciclosporin once daily in food or per os for 6 weeks is effective and well tolerated in feline HD.

Responsiveness and validity of the SCORFAD, an extent and severity scale for feline hypersensitivity dermatitis

“…This was first verified by assessing the response to various interventions, with the observation that the SCORFAD values decreased in parallel with the administration of interventions that had increasing anti‐inflammatory effect (i.e. placebo and ciclosporin at 2.5 and 7.0 mg/kg) 19 . Furthermore, the sensitivity of this scale to change depended upon the selected outcome measures.…”

Dose tapering for ciclosporin in cats with nonflea‐induced hypersensitivity dermatitis

“…Ciclosporin has been used for many years in the treatment of feline hypersensitivity dermatitis at various doses, generally ranging from 5 to 10 mg/kg . The dose of 7 mg/kg given daily has recently been tested in a randomized, blinded parallel group, placebo‐controlled study and was shown to be efficacious and well tolerated . In cats with head and neck excoriations, self‐induced alopecia, eosinophilic plaque and/or miliary dermatitis, the administration of 7 mg/kg ciclosporin daily for 6 weeks resulted in a decrease in total lesion and owner‐assessed pruritus severity scores.…”

Clinical efficacy and safety following dose tapering of ciclosporin in cats with hypersensitivity dermatitis

“…Treatment at a dose of 7 mg/kg for up to 6 weeks was shown to be efficacious and well tolerated. 4 The current study, including a large population of cats, shows that following 7 mg/kg per day of CsA for a minimum of 4 weeks, the frequency of CsA administration could be reduced to EOD while maintaining control of HD in >70% of treated cats. The dosing frequency could be further reduced to TW in 53% of treated cats.…”

“…4 An overall assessment of clinical response (scored from 0 to 4) was made by the investigator and the owner at each visit of the phase 2 study beginning at V2.…”